TY  - CHAP
M1  - Book, Section
TI  - Vitiligo
A1  - Ezzedine, Khaled
A1  - Harris, John E.
A2  - Kang, Sewon
A2  - Amagai, Masayuki
A2  - Bruckner, Anna L.
A2  - Enk, Alexander H.
A2  - Margolis, David J.
A2  - McMichael, Amy J.
A2  - Orringer, Jeffrey S.
PY  - 2019
T2  - Fitzpatrick's Dermatology, 9e
AB  - AT-A-GLANCEVitiligo  is  a  common  autoimmune  disease  of  the  skin  that  causes  depigmentation  through  T-cell–mediated  destruction  of  melanocytes.Pathogenesis  is  multifactorial,  including  genetic  predisposition,  autoimmunity,  and  environmental  factors.Vitiligo  can  cause  significant  social  stigma,  with  serious  implications  for  mental  health.Correlates  with  increased  risk  of  other  autoimmune  diseases,  but  decreased  risk  of  skin  cancer.Clinical  signs  of  lesional  activity  include  confetti,  trichrome,  and  inflammatory  lesions,  as  well  as  koebnerization.Reversible  with  treatment,  but  only  in  areas  with  normally  pigmented  hair.Effective  treatments  include  topical  and  oral  immunosuppressants,  phototherapy,  and  chemical  depigmenting  agents.Emerging  treatments  include  targeted  immunotherapy  and  melanocyte-stimulating  hormones.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1161324334
ER  -